Skip to main content
. 2015 Aug 14;29(9):1141–1151. doi: 10.1038/eye.2015.131

Figure 3.

Figure 3

Percentages of study participants with improved (gain of ≥3 lines), stable (gain or loss of <3 lines), or worsened (loss of ≥3 lines) best-corrected visual acuity (BCVA) after anti-vascular endothelial growth factor (VEGF) monotherapy for large submacular hemorrhage (SMH).